Frequent genetic alterations in hematopoietic neoplasias (chromosomal translocations, point mutations, etc.) have provided biologic targets for the development of effective novel therapies. A rapidly increasing body of knowledge provides evidence also for multiple epigenetic alterations in these disorders, which can complement or even precede genetic aberrations. Gene inactivation ('silencing') of tumor suppressor and growth inhibitory genes (e.g. the cyclin-dependent kinase inhibitors p16, p15, p21) is frequently mediated by DNA methylation of gene promoters. The acetylation state of histones (functionally linked to the DNA methylation state by the methylcytosine binding protein 2, recruiting histone deacetylases) provides a second major epigenetic silencing mechanism. Therapeutic reversal strategies are being developed for acute leukemias, myelodysplastic syndromes and malignant lymphomas. Since the discovery of the DNA methyltransferase (Dnmt) inhibitory activity of two azanucleosides (5-azacytidine, 5-aza-2 0 -deoxycytidine/ decitabine) even at doses with minimal nonhematologic toxicity, both have been clinically studied in several myeloid neoplasias, particularly in elderly patients unable to tolerate aggressive treatment. Further development of agents counteracting aberrant methylation is directed at more targeted approaches, for example, antisense molecules against Dnmts. Histone deacetylases (HDACs) can be inhibited by numerous compounds (sodium phenylbutyrate, valproic acid, novel compounds such as depsipeptide), which have entered the clinical arena in similar indications as Dnmt inhibitors. Impressive effects of HDAC inhibition in acute promyelocytic leukemia models (PML/RARA expression) translate the finding of HDAC recruitment by this chimeric transcription factor to its target genes. The recent discovery of recruitment by PML/RARA also of Dnmt activity to the retinoic acid receptor-beta promoter makes it an interesting candidate for Dnmt inhibitors. Studies combining a 're-expressor' strategy with inhibitors of Dnmts and HDACs are underway. Thus, resensitization to biological agents such as retinoids, colony-stimulating factors and other differentiation inducers may be envisioned.
Introduction
Approximately 3-5% of all cytosines are methylated in the vertebrate genome (Jaenisch and Bird, 2003) . 5-Methylcytosine differs from cytosine by addition of a methyl group at the C5 position of the pyrimidine ring when present in a CpG dinucleotide (Figure 1 ). The transfer of methyl groups from S-adenosyl-l-methionine (SAM) to cytosine is a heritable mechanism that is catalysed by several DNA methyltransferases (DNMTs) during cell replication. At least three different DNMTs are involved in cellular DNA methylation: DNMT1, DNMT3A, DNMT3B and splicing variants (Singal and Ginder, 1999; Robertson and Wolffe, 2000) . In somatic cells, DNMT1 shows highest activity and affinity to hemimethylated DNA, being mainly responsible for maintaining methylation patterns during replication ('maintenance methyltransferase'). DNMT3A and -3B are equally effective in methylation of hemimethylated and unmethylated DNA, and they are required for de novo methylation (Okano et al., 1999) .
CpG dinucleotides are strongly under-representated in the mammalian genome, which is due to spontaneous deamination of the relatively unstable base 5-methylcytosine to uracil having caused strong depletion during evolution. In contrast to the rest of the genome, smaller specific regions show high density of CpG dinucleotides (Bird, 1986) . These regions are called CpG islands if they fulfill certain criteria (Gardiner-Garden and Frommer, 1987; Cross and Bird, 1995) : size ranging from 200 bp to 5 kb, occurring on average every 100 kb, being GC-rich (60-70%) and not showing suppression of CpG frequency (CpG/GC ratio 40.6). CpG-rich regions (CpG islands) are most often found within regulatory regions of the genome, mainly promoters (Bird, 1986) . Nonpromoter CpG dinucleotides are mainly located in repetitive DNA regions like Alu repeats (Graff et al., 1997) .
CpG island methylation is associated with changes in chromatin structure and repression of gene transcription (Baylin et al., 1998) . In non-neoplastic tissues, promoter methylation can be found mainly in two settings, selectively silenced alleles in imprinted genes (Barlow, 1995) and genes located on the inactivated X-chromosome in females (Goto and Monk, 1998) . The mechanisms of transcriptional repression are not fully understood yet, they involve direct interactions of methylated DNA with certain regulatory proteins, binding of methylated DNA binding proteins (MBPs) and recruitment of silencing complexes (Bird and Wolffe, 1999) . MBPs, for example, methyl-CpG binding protein 2 (MeCP2) (Jones et al., 1998) , which contain methyl CpG-binding (MBD) and transcriptional repression domains (TRD), build complexes with corepressors that include histone deacetylases (HDACs) (Figure 2 ). This hypothesis is supported by the observation that the HDAC inhibitor Trichostatin A (TSA) partially relieves transcriptional inactivation in hypermethylated genes. The interactions of DNMTs, MBPs and HDACs provide a synergistic connection of DNA methylation and histone deacetylation in transcriptional repression (Jahangeer et al. 1982; Cameron et al, 1999 , Jones and Wolffe, 1999 , Shaker et al., 2003 . Recently, histone methylation via histone methyltransferases (HMTs) has been discovered as a major additional silencing chromatin modification (Kouzarides, 2002; Jaenisch and Bird, 2003) , probably supplementing the linkage of DNA methylation and histone deacetylation in repressing in appropriate transcription.
Global and gene-specific DNA methylation in normal and malignant myeloid cells
Comparisons of genomewide content in cytosine methylation between normal and transformed hematopoietic cells have revealed hypomethylation in acute myeloid leukemia (AML) during progression of the disease (Pfeifer et al., 1988) . Genomewide hypomethylation also occurs in chronic lymphocytic leukemia, whereas in that study acute leukemias showed overall levels that were comparable to normal leukocytes (Wahlfors et al., 1992) . Hematopoietic precursor cells (CD34 þ ) have served as a model to study gene-specific methylation changes during in vitro differentiation. A decrease of a initially fully methylated lysozyme gene was noted at least concomitantly with in vitro differentiation and transcriptional upregulation of lysozyme expression, whereas the methylation of CD34 and MPO was unchanged despite changes in expression (Lu¨bbert et al., 1996) . The p15 gene in normal CD34 þ cells is unmethylated (Teofili et al., 2000 (Teofili et al., , 2001 , becomes methylated after 7 days of in vitro differentiation, and demethylated after prolonged culturing (Sakashita et al., 2001) .
In hematopoietic neoplasias, large numbers of genes have been studied for methylation changes compared to their untransformed cellular counterparts. These have been recently reviewed by Chim et al. (2002) , and the results are summarized in Table 1 . Investigations have focused on genes involved in cell cycle regulation (several of them proven or bona fide tumor suppressor genes), genes involved in growth, differentiation and signalling, metastasis and other functions appearing as reasonable candidates during neoplastic transformation. A certain lineage specificity of the genes being inactivated by methylation is apparent: p15 is frequently hypermethylated in myeloid neoplasias and acute lymphoid leukemia, whereas p16, which is only rarely involved in myeloid neoplasms, is frequently methylated in non-Hodgkin's lymphoma (Drexler, 1998) .
One study has reported overexpression of several methyltransferases in acute myeloid leukemia, which may be at least in part responsible for gene hypermethylation in that disorder (Mizuno et al., 2001) . A different mechanism of promoter methylation was demonstrated in the leukemia model of acute promyelocytic leukemia (APL) expressing the chimeric transcription factor PML/RARa (Di Croce et al., 2002) . It was shown that PML/RARa was able to mediate silencing by DNA methylation of the target gene RARb, via recruitment of DNMT3a. Treatment of cells with retinoic acid induced demethylation of this promoter, with gene re-expression and reversion of the malignant phenotype by differentiation. By these results, a mechanistic link between genetic changes in leukemia and epigenetic modification during transformation was first demonstrated. Hypermethylation thus contributed to early steps in leukemogenesis, at least in this subtype of leukemia, prompting similar analyses also in other leukemias bearing oncogenic transcription factors. The availability of high-throughput methylation analyses based on bisulfite treatment, and the development of global scanning assays such as the restriction landmark genomic scanning (RLGS) allowed analysis of multiple candidate methylation targets and even unknown sequences in hematologic neoplasias. Most of these studies were performed on primary cells from AML. Melki et al. (1999) first described concurrent DNA hypermethylation of multiple genes in this disorder, demonstrating abnormal methylation patterns in 95% of AML samples analysed, with 75% hypermethylation in two or more of the target genes. This analysis also indicated a cancer type-specific methylation pattern, with frequent methylation of p15, calcitonin and E-cadherin as well as HIC1, and no methylation at the RB and GST-pi loci. Another study analysed 14 promoter-associated CpG islands in AML and found a positive correlation of methylation of p15, p16, CACNA1G, MINT1, MINT2, MDR1, THBS1 and PTC1 with estrogen receptor (ER) methylation density ). Interestingly, this study found the highest levels of methylation in MYOD1, PITX2, GPR37 and SDC4 (47-64% of the 36 patients), which were also positively correlated with ER methylation density. A statistically significant inverse correlation between age of the patients and number of genes methylated was also noted, in line with the observation that methylation in normal colonic tissue increased with age.
A detailed and comparative methylation mapping of both the promoter and coding regions of p15, p16 and PAX6 in AML, myelodysplastic syndrome (MDS) and CML has revealed recurrent promoter methylation only of the p15, but not of the other two genes, whereas the exonic regions of all three genes showed de novo methylation (compared to normal blood cells) in all hematologic disorders. Exonic CpG islands showed a higher susceptibility to de novo methylation than the respective promoters, and thus may act as seeds from which methylation spreads, supporting the observation of concurrent methylation of multiple genes (Nguyen et al., 2001) . The widest CpG island methylation analysis performed thus far in leukemia, employing RLGS two-dimensional electrophoresis, provided methylation information on 33 methylated loci Batova et al. (1997) , Baur et al. (1999) , Baylin et al. (1986 Baylin et al. ( , 1987 including 21 known genes or ESTs. A comparative analysis showed five of these loci to be methylated solely in AML but not in solid tumors (Rush et al., 2001) . Interestingly, chromosomal mapping of methylated loci showed a preponderance of genes on chromosome 11.
Development of demethylating agents for reversion of 'epigenetic silencing' by promoter hypermethylation
Two azanucleosides (Figure 1 ) first synthesized in 1964 were developed for cytostatic treatment primarily of acute leukemias, with further clinical trials also directed at solid tumors. Until the discovery of the potency of both azanucleosides to act as demethylating agents (reviewed by Jones and Laird, 1999) , a large body of clinical trials particularly with 5-azacytidine at intermediate to high doses in acute leukemia showed effectivity that was comparable to equitoxic doses of cytarabine (reviewed by Lu¨bbert, 2000; Santini et al., 2001) . At higher doses, the specific demethylating activity of these compounds (by irreversibly binding Dnmt1, see Figure 3 ), may be subordinate to a substantial cytotoxicity presumably not mediated by demethylation (particularly nonhematologic toxicity such as mucositis and CNS toxicity) of those schedules. Therefore, studies begun in the mid-to late-1980 s aimed the treatment of mostly older patients unfit for standard induction treatment of acute leukemia, and capitalized upon the demethylating activity of both drugs seen in vitro at lower concentrations. Since then, both compounds have been studied in large phase II trial in patients with MDS. A phase III trial of 5-azacytidine subcutaneously on 7 days, compared to best supportive care with the option of delayed treatment with 5-azacytidine at time of progression, showed a statistically significant difference in transformation to AML as the first event (21 months median time to AML or death in 5-azacytidine-treated patients vs 13 months in patients treated with supportive care only; Silverman et al., 2002) . Although by its design this trial could not test the hypothesis that treatment with this azanucleoside results in prolonged survival, the first showed an influence upon the natural course of MDS with any treatment. The complete hematologic response rate in this trial was 7% and paralleled by a rate of cytogenetic normalization of 8.4% (Najfeld et al., 2002) . Decitabine, the more potent DNA demethylating agent, resulted in a 20-25% hematologic complete response rate and a 31% rate of cytogenetic normalization when given intravenously over 72 h (Wijermans et al., 1997 (Wijermans et al., , 2000 Lu¨bbert et al., 2001) . Interestingly, cytogenetic normalization appeared more frequently in MDS with 'poor risk' than 'intermediate risk' karyotype. Based on these results, a European phase III trial is now testing the hypothesis that treatment with the decitabine results in a prolongation of survival in elderly patients with high-risk MDS. Deaths during the first 6 months not caused by transformation to AML were below 10% in trials with both azanucleosides. Other trials using low-dose schedules of decitabine as a demethylating agent in hematologic neoplasias are aimed at patients with chronic myeloid leukemia (Santini et al., 2001 ) and acute myeloid leukemia Lu¨bbert et al., 2002) as single agents. An in vivo modulatory effect of low-to-intermediate doses of decitabine upon gene regulation was first studied by Pinto et al. (1984) , with upregulation HLA-DR on leukemic blasts from patients with AML treated with decitabine. Other membrane-bound molecules upregulated by low-dose decitabine were CD11c, CD14, CD16, which may be related to induction of the differentiation program in these myeloid blasts. Results compatible with partial maturation (downregulation of CD34) was also described by Richel et al. (1991) in AML patients treated with decitabine and amsacrine. A recent study examining the expression of cancer testis antigens (CTAs) on myeloid blasts during treatment with decitabine and low-to-intermediate doses noted lack of expression of three CTAs (MAGE1, SSX, NY-ESO-1) in 9/11 patients. Following decitabine treatment, these genes were upregulated in eight of nine cases (Sigclotti et al., 2003) . In all studies, peripheral blood leukemic blasts were amenable to analysis, making gene expression changes caused by emergence of normal hematopoietic cells unlikely. Daskalakis et al. (2002) studied p15 methylation and expression in bone marrow cells from patients with highrisk MDS before, during and after treatment with low-dose decitabine. Whereas the p15 gene was hypermethylated in 65% of the patients prior to treatment, methylation was reduced already during the initial courses of treatment, at least concomitantly with clinical response. Allele-specific methylation analysis and parallel cytogenetic studies implied demethylation of cells belonging to the dysplastic clone as the most likely explanation. Suppressed p15 expression in bone marrow myeloid precursors was upregulated in half the patients in whom initial hypermethylation was reversed during treatment. Thus, p15 appears as a candidate for proof of in vivo demethylation by an azanucleoside. In a similar study by Issa et al. (2001) , treating patients with refractory myeloid malignancies with a de-escalating decitabine dose schedule to determine the minimal dose affecting demethylation, responses were seen in 10/30 refractory relapsed AML patients, in 3/4 MDS and 2/2 CML patients, p15 demethylation could be observed 5 days after treatment in two patients who subsequently achieved remission. The group of Steven Gore conducted p15 methylation studies in a similar dose deescalation design, combining 5-azacytidine and the HDAC inhibitor phenylbutyrate (see below). In all, 9/9 patients with MDS or AML had p15 promoter methylation exceeding 10%. In three patients, p15 methylation decreased, whereas it increased in one patient (associated with disease progression) and was stable in five patients .
These in vivo observations of a silenced p15 gene being activated by treatment with demethylating agents provide proof of principle that reactivation can occur at dose schedules with low or minimal nonhematologic toxicity. However, even in a morphologically homogeneous blast population of acute leukemia, the argument that cells with a lower methylation status are being selected for cannot be ruled out. It is conceivable that these drugs have the strongest antileukemic activity upon subpopulations of cells with the highest methyltransferase expression, which by complexing with DNA strands having incorporated a deoxy-azanucleoside molecule may cause DNA damage (Jaenisch and Bird, 2003) . The recurrent observation of blast clearance in the peripheral blood being markedly slower than with cytarabine or other low-dosed chemotherapy treatment is quite compatible with lower proliferation, and activation of apoptosis subsequent to initial DNA incorporation of the methyltransferase inhibitor. Open questions are: which of the genes being reactivated (since reactivation of p15 alone is not likely) or combination of genes is biologically most relevant in a given tumor tissue type; is a 'methylation phenotype' (defined by methylation of one or more silenced genes) in a given hematologic neoplasia predictive for response to demethylation agents? This awaits clarification in prospective clinical trials with parallel methylation analyses (Leone et al., 2002) .
Pharmacologic inhibition of histone deacetylation
Regional chromatin folding is determined by distinct modifications at tail ends of histone proteins. This mechanism is highly regulated and results in either transcriptional repression (by histone deacetylation and subsequent 'closing' of the chromatin) or transcriptional activation by histone hyperacetylation (with subsequent chromatin remodeling, resulting in an 'opening' allowing access of the transcriptional machinery to gene promoters, see Figure 2 ). Histone acetyltransferases (HATs) as well as HDACs mediate the acetylation state of histones, and their balance of activity is altered in malignancies. In vitro, gene reactivation by treatment of leukemia cell lines with inhibitors of HDACs results in differentiation or apoptosis in myeloid neoplasias (Garber, 2002) . Particularly, APL provides a welldefined, powerful model of HDAC dysregulation resulting in a malignant phenotype that may be targeted by pharmacologic inhibition of HDACs: PML/RARamediated gene inactivation of retinoic acid receptor-beta and other target genes of RAR-alpha has been extensively studied (Grignani et al., 1998; He et al., 2001; Lin et al., 1998) . The leukemia-specific fusion protein has the ability to suppress by recruitment of an HDAC, resulting in local chromatin remodelling. Warrell et al. (1998) first described in vivo results of a 'therapeutic targeting of transcription' in a case of APL by pharmacologic HDAC inhibition. A patient having suffered multiple relapses of APL was treated with all-trans retinoic acid (ATRA) followed by the HDAC inhibitor sodium phenyl butyrate (SPB). Although her disease had become ATRA-resistant, the combination resulted in restoration of ATRA sensitivity, and the patient achieved a complete hematologic and molecular remission. Studies of histone H3 and H4 acetylation from her peripheral blood and bone marrow cells revealed a marked in vivo acetylation of both histone fractions already 2 h after beginning of SPB infusion and this effect lasted over several hours (Warrell et al., 1998) . Although further clinical studies in refractory APL showed variable activity, this drug combination resulted in impressive disease control in a transgenic mouse model (He et al., 2001) .
The in vivo single-agent activity of SPB is not limited to leukemia with a chimeric transcription factor proven to recruit HDAC activity to target genes. Several clinical trials have been undertaken to determine the maximum tolerated dose and clinical activity of SPB in patients with MDS and AML. A phase I study performed at Johns Hopkins revealed 375 mg/kg/day as 7-day continuous infusion as the optimal dose, with higher doses resulting in reversible neurocortical toxicity . With repetition every 4 weeks, four out of 27 patients achieved a hematologic improvement of either neutrophil counts or platelet counts. Although no complete or partial remissions were achieved, this activity, and effective steady-state plasma concentrations in the nanomolar range, prompted combination trials of SPB with 5-azacytidine, in which no unexpected clinical toxicity has been noted (Camacho et al., 2001; Miller et al., 2001) . A number of other compounds with diverse chemical structures, but proven HDAC inhibitory activity, have entered the clinical arena ( Table 2) . Many of these are being developed for the treatment of hematopoietic neoplasias. The HDAC inhibitor depsipeptide (FR901228) was studied in AML1/ETOpositive Kasumi-1 cells and primary leukemic blasts of this subtype. Dose-dependent increases in acetylation of H3 and H4 histones, in cytotoxicity and IL-3 expression (a target gene of AML1) were noted. This effect was enhanced by decitabine. However, the activity of depsipeptide was not limited to AML1/ETO-positive cells (Klisovic et al., 2003) .
Comparable results were obtained by the group 4 of Momparler (Shakar et al., 2003) . We examined the effect of TSA alone and in combination with Decitabine upon growth, viability and gene expression in AML1/ ETO positive vs AML1/ETO negative cells (Claus et al., 2003) . Both compounds resulted in growth inhibition of AML1/ETO cells at low cytotoxic doses, and independently upregulated the lysozyme gene, which is methylated and has an 'closed' chromatin structure. TSA treatment resulted in hyperacetylation of H3 and H4, whereas only decitabine led to demethylation of the lysozyme gene promoter and exonic CpG-island. Morphologic changes and marker gene expression were not typical for differentiation but indicated apoptosis. The suppression of lysozyme expression by induction of AML1/ET11 in an inducible system was neutralized by treatment with TSA. In summary, a combined treatment of AML1/ETO-positive leukemia with demethylating agents followed by HDAC inhibitors may be more effective than in other subtypes of myeloid leukemia. Since valproic acid, an antiepileptic oral compound used for decades, was also demonstrated recently to have HDAC inhibitory activity (Go¨ttlicher et al., 2001) , studies are underway to determine the optimal dose of this agent in relapsed/refractory leukemia, and a study combining valproic acid (or other effective HDAC inhibitors) with the differentiating agent ATRA is ongoing (Ku¨ndgen et al., 2003) .
Conclusions and future directions
While the methylation machinery in normal hematopoietic development is regulated to allow lineage-specific differentiation and control of proliferation, disturbances in methylation leading to gene-specific inactivation by promoter silencing have been recognized as a key epigenetic mechanism during malignacy transformation. Results derived from the APL and MDS indicate that hypermethylation may be an early event during leukemogenesis. Tumor suppressor gene silencing by hypermethylation fulfills criteria of Knudson's hypothesis of a 'first hit' followed by deletion or mutation of a second allele. In hematopoietic neoplasias, multiple genes may be hypermethylated, with a preponderance of p16 methylation evident in lymphoma, whereas p15 is frequently methylated in myeloid neoplasias. Methylation of these genes may have prognostic relevance, which needs to be valuated in prospective clinical studies. Beyond methylation analyses of single genes, a global gene methylation pattern is necessary to further refine the diagnostic and prognostic impact of these epigenetic changes.
As therapeutic targets, both gene hypermethylation and hypoacetylation of histones are models for which therapeutic interventions are being developed. Two azanucleosides (5-azacytidine and decitabine) are being clinically developed for use in myeloid neoplasias. Both offer a low-dose administration aimed at a very acceptable nonhematologic toxicity. The mechanism of action of both azanucleosides may be unique and thus distinct from the effects attributed to low-dose cytarabine or other low-dose chemotherapy. Specifically, evidence is mounting that demethylation of target genes by treatment with these drugs occurs not only in vitro (shown in virtually hundreds of studies using cell lines), but also in patients treated with methylation inhibitor on a single-cell level. However, further studies are necessary to define better the target cells of this approach and to differentiate demethylation of genes that are 'innocent bystanders' in a more general hypermethylator phenotype, from genes in which evidence points towards Combination treatment of demethylating agents and histone deacetylase inhibitors will form a basis for removing epigenetic gene inactivation, thus resensitizing cells for growth and differentiation inducing signals, for instance with retinoids, vitamin D 3 analogues and colony-stimulating factors. Clinical approaches may be envisioned combining these compounds in order to achieve differentiation and/or alteration of apoptotic pathways in myeloid and lymphoid neoplasias. Elderly patients who may not tolerate standard intensive chemotherapy for example for acute myeloid leukemia, are a particularly important group of patients for whom this type of treatment can be developed.
